Table 2.
Comparison of changes in the parameters of patients treated with ezetimibe combination or statins after 1 year.
| Ezetimibe Combination (n = 43) | Statin Monotherapy (n = 90) | Difference between Groups | |||||
|---|---|---|---|---|---|---|---|
| Baseline | Post-Treatment | p Value | Baseline | Post-Treatment | p Value | p Value | |
| Glucose, fasting (mg/dL) | 106.0 (18.0) | 105.0 (20.0) | 0.296 | 99.0 (17.0) | 101.0 (17.3) | 0.021 | 0.996 |
| Glucose, stimulated (mg/dL) | 118.0 (58.0) | 127.0 (52.5) | 0.946 | 111.0 (30.0) | 132.0 (54.0) | 0.016 | 0.117 |
| Insulin, fasting (uU/mL) | 7.0 (3.8) | 7.3 (4.6) | 0.828 | 6.2 (3.6) | 7.3 (4.1) | 0.003 | 0.066 |
| HOMA-IR | 1.7 (0.9) | 1.8 (1.3) | 0.923 | 1.5 (0.9) | 1.8 (1.1) | 0.002 | 0.109 |
| HbA1c (%) | 6.0 (0.9) | 5.9 (0.8) | 0.793 | 5.9 (0.4) | 5.9 (0.3) | 0.758 | 0.865 |
| AST (IU/L) | 21.0 (6.0) | 23.0 (9.0) | 0.003 | 21.0 (8.0) | 23.0 (7.0) | 0.009 | 0.825 |
| ALT (IU/L) | 18.0 (9.0) | 23.0 (21.0) | 0.012 | 18.0 (9.5) | 21.0 (13.0) | 0.003 | 0.694 |
| Total cholesterol (mg/dL) | 241.0 (61.0) | 167.0 (47.0) | <0.001 | 232.0 (47.5) | 168.5 (40.3) | <0.001 | 0.850 |
| Triglycerides (mg/dL) | 125.0 (84.0) | 116.5 (71.0) | 0.347 | 132.0 (68.0) | 110.5 (76.8) | 0.014 | 0.629 |
| HDL cholesterol (mg/dL) | 53.0 (15.0) | 51.5 (18.3) | 0.175 | 52.0 (15.0) | 52.0 (16.3) | 0.077 | 0.830 |
| LDL cholesterol (mg/dL) | 154.0 (60.4) | 82.9 (38.8) | <0.001 | 150.2 (52.0) | 90.0 (30.2) | <0.001 | 0.566 |
The data are presented as a median (IQR), and the p values were obtained from the Wilcoxon signed-rank test. The difference in p values was determined via intention-to-treat analysis.